FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated Advanced Colorectal Cancer
Evidence for efficacy is based on the results from the KRYSTAL-1 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
Second- or Third-Line Treatment with Tisotumab Vedotin Results in Greater Efficacy than Chemotherapy in Patients with Recurrent Cervical Cancer
Findings from the innovaTV 301/ENGOT-cx12/GOG-3057 study
A Meaningful Benefit of the Quadruplet-Based Isatuximab Plus VRd Regimen in Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Findings from the IMROZ and BENEFIT studies
EMA Recommends Granting a Marketing Authorisation for Erdafitinib
It is intended for the treatment of patients with urothelial carcinoma harbouring FGFR3 alterations
Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than Placebo Among Patients with Resected Stage III Melanoma with BRAF V600 Mutations
Final results of the COMBI-AD study
FDA Grants Accelerated Approval to Repotrectinib for Adult and Paediatric Patients with NTRK Gene Fusion-positive Solid Tumours
Evidence for efficacy is based on the results from the TRIDENT-1 study
Amivantamab Plus Lazertinib Shows Superior Efficacy to Osimertinib in First-Line Treatment for EGFR-mutated Advanced NSCLC
Findings from the MARIPOSA study
Treatment with Brigatinib Results in Radiographic Responses and Clinical Benefit in a Heavily Pretreated Cohort of Patients with NF2-Related Schwannomatosis
Findings from the INTUITT-NF2 study
Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated Patients with Relapsed or Refractory Multiple Myeloma
Findings from the DREAMM-7 and DREAMM-8 studies
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer
Evidence for efficacy is based on the results from the LIBRETTO-001 study
Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping Compared with Cytology to Triage HPV-positive Women
Findings from a real-life cohort of women aged at least 30 years who attended cervical cancer screening in Stockholm
EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride / Gallium (68Ga) chloride
It is indicated for in vitro radiolabelling of various kits for radiopharmaceutical preparation developed and approved for radiolabelling used for PET imaging